Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Consensus Rating of “Hold” by Brokerages

Neumora Therapeutics, Inc. (NASDAQ:NMRA) has earned a consensus recommendation of “Hold” from the ten ratings firms that are presently covering the firm, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating on the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $8.00.

NMRA has been the subject of a number of recent analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Neumora Therapeutics in a research note on Wednesday, October 8th. Royal Bank Of Canada upgraded Neumora Therapeutics from a “sector perform” rating to an “outperform” rating and boosted their target price for the company from $4.00 to $7.00 in a research report on Monday, December 1st. Needham & Company LLC upped their target price on Neumora Therapeutics from $6.00 to $8.00 and gave the company a “buy” rating in a research note on Tuesday, October 28th. Stifel Nicolaus raised their price target on Neumora Therapeutics from $2.00 to $3.00 and gave the stock a “hold” rating in a research note on Monday, November 17th. Finally, JPMorgan Chase & Co. cut Neumora Therapeutics from a “neutral” rating to an “underweight” rating in a report on Tuesday, September 16th.

Insider Buying and Selling

In related news, major shareholder Arch Venture Partners Xii, Llc purchased 1,915,700 shares of Neumora Therapeutics stock in a transaction that occurred on Monday, October 27th. The shares were bought at an average price of $2.61 per share, with a total value of $4,999,977.00. Following the purchase, the insider directly owned 6,046,907 shares of the company’s stock, valued at approximately $15,782,427.27. This represents a 46.37% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Daljit Singh Aurora sold 114,703 shares of Neumora Therapeutics stock in a transaction dated Tuesday, November 11th. The shares were sold at an average price of $2.68, for a total transaction of $307,404.04. Additional details regarding this sale are available in the official SEC disclosure. 26.80% of the stock is currently owned by insiders.

Institutional Trading of Neumora Therapeutics

Large investors have recently modified their holdings of the company. Vanguard Personalized Indexing Management LLC grew its stake in Neumora Therapeutics by 10.7% in the third quarter. Vanguard Personalized Indexing Management LLC now owns 64,429 shares of the company’s stock worth $117,000 after purchasing an additional 6,233 shares in the last quarter. Invesco Ltd. lifted its holdings in shares of Neumora Therapeutics by 6.8% in the 2nd quarter. Invesco Ltd. now owns 132,038 shares of the company’s stock worth $97,000 after buying an additional 8,383 shares during the period. CWM LLC grew its position in shares of Neumora Therapeutics by 41.8% during the 2nd quarter. CWM LLC now owns 35,750 shares of the company’s stock worth $26,000 after buying an additional 10,537 shares in the last quarter. Legacy Private Trust Co. purchased a new position in shares of Neumora Therapeutics during the third quarter valued at $25,000. Finally, Virtu Financial LLC purchased a new position in shares of Neumora Therapeutics during the third quarter valued at $31,000. Hedge funds and other institutional investors own 47.65% of the company’s stock.

Neumora Therapeutics Stock Performance

NASDAQ NMRA opened at $1.83 on Thursday. The business’s 50 day moving average price is $2.30 and its 200-day moving average price is $1.78. Neumora Therapeutics has a fifty-two week low of $0.61 and a fifty-two week high of $11.57. The company has a market cap of $304.94 million, a P/E ratio of -1.24 and a beta of 3.12. The company has a debt-to-equity ratio of 0.15, a quick ratio of 6.85 and a current ratio of 6.85.

Neumora Therapeutics (NASDAQ:NMRA) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.01). Sell-side analysts predict that Neumora Therapeutics will post -1.61 earnings per share for the current year.

Neumora Therapeutics Company Profile

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.